title: Outcomes from a patient-centered residential treatment plan for tobacco dependence.
abstract: St. Helena Hospital launched the first US residential stop-smoking program, The St. Helena Center for a Smoke-Free Life, in 1969. This observational report describes the center's treatment outcome rate for using a patient-centered approach to the use of tobacco dependence medications and behavioral treatment for patients who participated in the program from January 1, 2005 through December 31, 2007. A total of 284 patients used long-acting (nicotine patch, bupropion, and varenicline) and/or short-acting medications (nicotine nasal spray, nicotine gum, nicotine lozenge, and nicotine oral inhaler) alone or in combination during treatment and after discharge. Seven patients chose to use no medications. Patients using nicotine patch received a mean ± SD dose of 33.3±15.7 mg of nicotine in 16 hours (range, 5-90 mg). The 12-month 7-day point prevalence smoking abstinence rate after participation in the intensive, 1-week, residential program was 57.0%. Recommendations are discussed for future research and for implementing aspects of the St. Helena program in other treatment settings.
authors.affiliation: Smoke-Free Life Program, St. Helena Center for Health, St. Helena, CA, USA. johnhodgkin@gmail.com
authors.forename: John E
authors.initials: JE
authors.lastname: Hodgkin
authors.forename: David P L
authors.initials: DP
authors.lastname: Sachs
authors.forename: Gary E
authors.initials: GE
authors.lastname: Swan
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Jack
authors.forename: Betsy L
authors.initials: BL
authors.lastname: Titus
authors.forename: Susan J S
authors.initials: SJ
authors.lastname: Waldron
authors.forename: Bonnie L
authors.initials: BL
authors.lastname: Sachs
authors.forename: Janet
authors.initials: J
authors.lastname: Brigham
mesh_terms: D001521:Behavior Therapy; D016642:Bupropion / Q000627:therapeutic use; D002140:California; D003131:Combined Modality Therapy; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010043:Outcome and Process Assessment, Health Care; D018802:Patient-Centered Care / Q000379:methods*; D016540:Smoking Cessation / Q000379:methods*; D061485:Tobacco Use Cessation Devices; D014029:Tobacco Use Disorder / Q000628:therapy*
chemical_list: D018765:Dopamine Uptake Inhibitors; D016642:Bupropion
keywords: FTND; Fagerström Test for Nicotine Dependence